Association between factors associated with colorectal cancer and rectal aberrant crypt foci in humans

Ezuka,Akiko; Sakai,Eiji; Kawana,Kenichi; Nagase,Hajime; Kakuta,Yukio; Uchiyama,Shiori; Ohkubo,Hidenori; Higurashi,Takuma; Nonaka,Takashi; Endo,Hiroki; Takahashi,Hirokazu; Nakajima,Atsushi

doi:10.3892/ol.2015.3763

Association between factors associated with colorectal cancer and rectal aberrant crypt foci in humans

Authors:
- Akiko Ezuka
- Eiji Sakai
- Kenichi Kawana
- Hajime Nagase
- Yukio Kakuta
- Shiori Uchiyama
- Hidenori Ohkubo
- Takuma Higurashi
- Takashi Nonaka
- Hiroki Endo
- Hirokazu Takahashi
- Atsushi Nakajima
View Affiliations

Affiliations: Department of Gastroenterology, Yokohama Rosai Hospital, Yokohama, Kanagawa 222‑0036, Japan, Department of Gastroenterology and Hepatology, Yokohama University School of Medicine, Yokohama, Kanagawa 236‑0004, Japan, Department of Pathology, Yokohama Rosai Hospital, Yokohama, Kanagawa 222‑0036, Japan
Published online on: September 29, 2015 https://doi.org/10.3892/ol.2015.3763
Pages: 3689-3695

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Aberrant crypt foci (ACF) are regarded as potential biomarkers for colorectal cancer (CRC), and have been used as such in recent early‑phase chemoprevention trials. However, the associations between the presence of ACF and other factors associated with the development of CRC, such as lifestyle factors, medication use and comorbid medical conditions, remain unknown. Thus, the present retrospective, large, cross‑sectional study was conducted to evaluate the potential usefulness of ACF as a surrogate biomarker of CRC. Total colonoscopy was performed and the number of rectal ACF was counted in a total of 902 subjects. A retrospective review of the medical records of the study subjects was performed, and the factors associated with the increased prevalence of ACF was investigated using univariate and multivariate logistic regression analyses. The analysis results identified older age [odds ratio (OR), 9.24; 95% confidence interval (CI), 4.80‑17.8; P<0.01], smoking habit (OR, 1.78; 95% CI, 1.20‑2.63; P<0.01) and use of insulin (OR, 9.97; 95% CI, 1.28‑77.5; P=0.03) as significant independent risk factors associated with the increased prevalence of ACF, regardless of the presence/absence of colon tumors. In addition, it was revealed that the prevalence and number of ACF, and the Ki‑67 labeling indices of the colonic epithelial cells were significantly higher in diabetic patients receiving insulin therapy than in those not receiving insulin therapy (P<0.01, P=0.03 and P=0.01, respectively). In conclusion, the potential usefulness of ACF as a surrogate biomarker of CRC was confirmed, although useful data could not be obtained on candidate chemopreventive agents. These results indicated that insulin can enhance colonic epithelial proliferative activity and induce the formation of ACF, thereby possibly triggering CRC development.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
2	Das D, Arber N and Jankowski JA: Chemoprevention of colorectal cancer. Digestion. 76:51–67. 2007. View Article : Google Scholar : PubMed/NCBI
3	Niitsu Y, Takayama T, Miyanishi K, Nobuoka A, Hayashi T, Kukitsu T, Takanashi K, Ishiwatari H, Abe T, Kogawa T, et al: Chemoprevention of colorectal cancer. Cancer Chemother Pharmacol. 54(Suppl 1): S40–S43. 2004.PubMed/NCBI
4	Boghossian S and Hawash A: Chemoprevention in colorectal cancer-where we stand and what we have learned from twenty year's experience. Surgeon. 10:43–52. 2012. View Article : Google Scholar : PubMed/NCBI
5	Hosono K, Endo H, Takahashi H, Sugiyama M, Sakai E, Uchiyama T, Suzuki K, Iida H, Sakamoto Y, Yoneda K, et al: Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer Prev Res (Phila). 3:1077–1083. 2010. View Article : Google Scholar : PubMed/NCBI
6	Takayama T, Nagashima H, Maeda M, Nojiri S, Hirayama M, Nakano Y, Takahashi Y, Sato Y, Sekikawa H, Mori M, et al: Randomized double-blind trial of sulindac and etodolac to eradicate aberrant crypt foci and to prevent sporadic colorectal polyps. Clin Cancer Res. 17:3803–3811. 2011. View Article : Google Scholar : PubMed/NCBI
7	Arber N, Eagle CJ, Spicak J, Rácz I, Dite P, Hajer J, Zavoral M, Lechuga MJ, Gerletti P, Tang J, et al: Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med. 355:885–895. 2006. View Article : Google Scholar : PubMed/NCBI
8	Grady WM and Carethers JM: Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology. 135:1079–1099. 2008. View Article : Google Scholar : PubMed/NCBI
9	Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM and Bos JL: Genetic alterations during colorectal-tumor development. N Engl J Med. 319:525–532. 1988. View Article : Google Scholar : PubMed/NCBI
10	Adler DG, Gostout CJ, Sorbi D, Burgart LJ, Wang L and Harmsen WS: Endoscopic identification and quantification of aberrant crypt foci in the human colon. Gastrointest Endosc. 56:657–662. 2002. View Article : Google Scholar : PubMed/NCBI
11	Bird RP: Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: Preliminary findings. Cancer Lett. 37:147–151. 1987. View Article : Google Scholar : PubMed/NCBI
12	Moxon D, Raza M, Kenney R, Ewing R, Arozullah A, Mason JB and Carroll RE: Relationship of aging and tobacco use with the development of aberrant crypt foci in a predominantly African-American population. Clin Gastroenterol Hepatol. 3:271–278. 2005. View Article : Google Scholar : PubMed/NCBI
13	Ohkubo H, Takahashi H, Yamada E, Sakai E, Higurashi T, Uchiyama T, Hosono K, Endo H, Taguri M and Nakajima A: Natural history of human aberrant crypt foci and correlation with risk factors for colorectal cancer. Oncol Rep. 27:1475–1480. 2012.PubMed/NCBI
14	Pretlow TP, Barrow BJ, Ashton WS, O'Riordan MA, Pretlow TG, Jurcisek JA and Stellato TA: Aberrant crypts: Putative preneoplastic foci in human colonic mucosa. Cancer Res. 51:1564–1567. 1991.PubMed/NCBI
15	Sakai E, Takahashi H, Kato S, Uchiyama T, Hosono K, Endo H, Maeda S, Yoneda M, Taguri M and Nakajima A: Investigation of the prevalence and number of aberrant crypt foci associated with human colorectal neoplasm. Cancer Epidemiol Biomarkers Prev. 20:1918–1924. 2011. View Article : Google Scholar : PubMed/NCBI
16	Seike K, Koda K, Oda K, Kosugi C, Shimizu K, Nishimura M, Shioiri M, Takano S, Ishikura H and Miyazaki M: Assessment of rectal aberrant crypt foci by standard chromoscopy and its predictive value for colonic advanced neoplasms. Am J Gastroenterol. 101:1362–1369. 2006. View Article : Google Scholar : PubMed/NCBI
17	Shpitz B, Bomstein Y, Mekori Y, Cohen R, Kaufman Z, Neufeld D, Galkin M and Bernheim J: Aberrant crypt foci in human colons: Distribution and histomorphologic characteristics. Hum Pathol. 29:469–475. 1998. View Article : Google Scholar : PubMed/NCBI
18	Takayama T, Katsuki S, Takahashi Y, Ohi M, Nojiri S, Sakamaki S, Kato J, Kogawa K, Miyake H and Niitsu Y: Aberrant crypt foci of the colon as precursors of adenoma and cancer. N Engl J Med. 339:1277–1284. 1998. View Article : Google Scholar : PubMed/NCBI
19	Endo H, Hosono K, Fujisawa T, Takahashi H, Sugiyama M, Yoneda K, Nozaki Y, Fujita K, Yoneda M, Inamori M, et al: Involvement of JNK pathway in the promotion of the early stage of colorectal carcinogenesis under high-fat dietary conditions. Gut. 58:1637–1643. 2009. View Article : Google Scholar : PubMed/NCBI
20	Endo H, Hosono K, Uchiyama T, Sakai E, Sugiyama M, Takahashi H, Nakajima N, Wada K, Takeda K, Nakagama H and Nakajima A: Leptin acts as a growth factor for colorectal tumours at stages subsequent to tumour initiation in murine colon carcinogenesis. Gut. 60:1363–1371. 2011. View Article : Google Scholar : PubMed/NCBI
21	McLellan E and Bird RP: Effect of disulfiram on 1,2-dimethylhydrazine- and azoxymethane-induced aberrant crypt foci. Carcinogenesis. 12:969–672. 1991. View Article : Google Scholar : PubMed/NCBI
22	McLellan EA and Bird RP: Specificity study to evaluate induction of aberrant crypts in murine colons. Cancer Res. 48:6183–6186. 1988.PubMed/NCBI
23	McLellan EA, Medline A and Bird RP: Sequential analyses of the growth and morphological characteristics of aberrant crypt foci: Putative preneoplastic lesions. Cancer Res. 51:5270–5274. 1991.PubMed/NCBI
24	Moghaddam AA, Woodward M and Huxley R: Obesity and risk of colorectal cancer: A meta-analysis of 31 studies with 70,000 events. Cancer Epidemiol Biomarkers Prev. 16:2533–2547. 2007. View Article : Google Scholar : PubMed/NCBI
25	Acott AA, Theus SA, Marchant-Miros KE and Mancino AT: Association of tobacco and alcohol use with earlier development of colorectal cancer: Should we modify screening guidelines? Am J Surg. 196:915–918. 2008. View Article : Google Scholar : PubMed/NCBI
26	Yuhara H, Steinmaus C, Cohen SE, Corley DA, Tei Y and Buffler PA: Is diabetes mellitus an independent risk factor for colon cancer and rectal cancer? Am J Gastroenterol. 106:1911–1921. 2011. View Article : Google Scholar : PubMed/NCBI
27	Higurashi T, Hosono K, Endo H, Takahashi H, Iida H, Uchiyama T, Ezuka A, Uchiyama S, Yamada E, Ohkubo H, et al: Eicosapentaenoic acid (EPA) efficacy for colorectal aberrant crypt foci (ACF): A double-blind randomized controlled trial. BMC Cancer. 12:4132012. View Article : Google Scholar : PubMed/NCBI
28	Mutch MG, Schoen RE, Fleshman JW, Takahashi H, Iida H, Uchiyama T, Ezuka A, Uchiyama S, Yamada E and Ohkubo H: A multicenter study of prevalence and risk factors for aberrant crypt foci. Clin Gastroenterol Hepatol. 7:568–574. 2009. View Article : Google Scholar : PubMed/NCBI
29	Luchtenborg M, White KK, Wilkens L, Kolonel LN and Le Marchand L: Smoking and colorectal cancer: Different effects by type of cigarettes? Cancer Epidemiol Biomarkers Prev. 16:1341–1347. 2007. View Article : Google Scholar : PubMed/NCBI
30	Stevens RG, Swede H, Heinen CD, Jablonski M, Grupka M, Ross B, Parente M, Tirnauer JS, Giardina C, Rajan TV, et al: Aberrant crypt foci in patients with a positive family history of sporadic colorectal cancer. Cancer Lett. 248:262–268. 2007. View Article : Google Scholar : PubMed/NCBI
31	Uchiyama T, Takahashi H, Endo H, Kato S, Sakai E, Hosono K, Yoneda M, Inamori M, Hippo Y, Nakagama H and Nakajima A: Number of aberrant crypt foci in the rectum is a useful surrogate marker of colorectal adenoma recurrence. Dig Endosc. 24:353–357. 2012. View Article : Google Scholar : PubMed/NCBI
32	Limburg PJ, Mahoney MR, Ziegler KL, Sontag SJ, Schoen RE, Benya R, Lawson MJ, Weinberg DS, Stoffel E, Chiorean M, et al: Randomized phase II trial of sulindac, atorvastatin and prebiotic dietary fiber for colorectal cancer chemoprevention. Cancer Prev Res. 4:259–269. 2011. View Article : Google Scholar
33	Cho NL, Redston M, Zauber AG, Carothers AM, Hornick J, Wilton A, Sontag S, Nishioka N, Giardiello FM, Saltzman JR, et al: Aberrant crypt foci in the adenoma prevention with celecoxib trial. Cancer Prev Res (phila). 1:21–31. 2008. View Article : Google Scholar : PubMed/NCBI
34	Larsson SC, Orsini N and Wolk A: Diabetes mellitus and risk of colorectal cancer: A meta-analysis. J Natl Cancer Inst. 97:1679–1687. 2005. View Article : Google Scholar : PubMed/NCBI
35	Deng L, Gui Z, Zhao L, Wang J and Shen L: Diabetes mellitus and the incidence of colorectal cancer: An updated systematic review and meta-analysis. Dig Dis Sci. 57:1576–1585. 2012. View Article : Google Scholar : PubMed/NCBI
36	Giovannucci E: Insulin, insulin-like growth factors and colon cancer: A review of the evidence. J Nutr. 131(Suppl 11): S3109–S3120. 2001.
37	Smith AJ, Stern HS, Penner M, Hay K, Mitri A, Bapat BV and Gallinger S: Somatic APC and K-ras codon 12 mutations in aberrant crypt foci from human colons. Cancer Res. 54:5527–5530. 1994.PubMed/NCBI
38	Takayama T, Ohi M, Hayashi T, Miyanishi K, Nobuoka A, Nakajima T, Satoh T, Takimoto R, Kato J, Sakamaki S and Niitsu Y: Analysis of K-ras, APC and beta-catenin in aberrant crypt foci in sporadic adenoma, cancer and familial adenomatous polyposis. Gastroenterology. 121:599–611. 2001. View Article : Google Scholar : PubMed/NCBI
39	Siu IM, Pretlow TG, Amini SB and Pretlow TP: Identification of dysplasia in human colonic aberrant crypt foci. Am J Pathol. 150:1805–1813. 1997.PubMed/NCBI
40	Hurlstone DP and Cross SS: Role of aberrant crypt foci detected using high-magnification-chromoscopic colonoscopy in human colorectal carcinogenesis. J Gastroenterol Hepatol. 20:173–181. 2005. View Article : Google Scholar : PubMed/NCBI